World Journal of
Pharmaceutical and Life Sciences

INVITRO EVALUATION OF ISONIAZID AND ITS DERIVATIVE (ISONIAZID:4-AMINOSALICYLIC ACID CO-CRYSTAL) FOR THE TREATMENT OF TUBERCULOSIS

Saniya Begum* and Dr. Syed Ahmed Hussain

ABSTRACT

Aim: This study investigates the antiTB properties of Isoniazid:4-aminosalicylic acid co-crystal against colorectal TB HT-29 cells and human umbilical vein endothelial cells (HUVECs). Objective: The primary objective is to evaluate the effects of this co-crystal on cell viability, angiogenesis, and the expression of key angiogenic markers such as NF-κB and VEGF-A. Research: Utilizing MTT assays, we assessed cell proliferation in HT-29 and HUVEC cell lines after treatment with various concentrations of Isoniazid:4-aminosalicylic acid co-crystal. The results indicated a significant decrease in cell viability for both cell lines. In the Tubulogenesis assay, a marked reduction in tubular structure formation was observed in HUVECs, indicating a potent anti-angiogenic effect. Furthermore, the Indirect Immunofluorescence and Western Blot analyses revealed decreased expression of NF-κB and VEGF-A in HT-29 cells, as well as reduced VEGFR-2 expression in HUVECs following treatment. Conclusion: The Isoniazid:4-aminosalicylic acid co-crystal shows promising antiTB and anti-angiogenic effects, highlighting its potential as a therapeutic agent in the treatment of colorectal TB. Further studies are necessary to elucidate its mechanisms of action and clinical applicability.

[Full Text Article]   [Download Certificate]